The loss of HER2, particularly the extracellular domain, has been predominantly observed in cancer cells resistant to non-ADC anti-HER2 antibody therapeutics because of reduced dependence on HER2 signaling and weakened immunological effects such as impaired antibody-dependent cellular cytotoxicity [26]. The gene discussed is ERBB2; the disease is cancer.